Free Trial
→ No. You’re not imagining it… (From Porter & Company) (Ad)tc pixel Free CHGCY Stock Alerts

Chugai Pharmaceutical (CHGCY) Stock Forecast & Price Target

Chugai Pharmaceutical logo
$25.37 0.00 (0.00%)
As of 05/22/2026 04:00 PM Eastern
Compare

Chugai Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Strong Buy
Based on 2 Analyst Ratings
Sell
0
Hold
0
Buy
2

Based on 2 Wall Street analysts who have issued ratings for Chugai Pharmaceutical in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 2 have given a strong buy rating for CHGCY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CHGCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Chugai Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHGCY Analyst Ratings Over Time

TypeCurrent Forecast
5/26/25 to 5/26/26		1 Month Ago
4/26/25 to 4/26/26		3 Months Ago
2/25/25 to 2/25/26		1 Year Ago
5/26/24 to 5/26/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
 N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingStrong BuyStrong BuyStrong BuyN/A

CHGCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHGCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Chugai Pharmaceutical Stock vs. The Competition

TypeChugai PharmaceuticalMedical CompaniesBroader Market
Consensus Rating Score
4.00
2.30
2.52
Consensus RatingStrong BuyHoldModerate Buy
Predicted UpsideN/A1,718.96% Upside15.10% Upside
News Sentiment Rating
Neutral News

See Recent CHGCY News
Neutral News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
2/25/2026
Smbc Nikko Sec. logo
Smbc Nikko Sec.
Not Rated
 UpgradeStrong-Buy
1/27/2026
UBS Group AG logo
UBS Group
4 of 5 stars
 UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:28 AM ET.


Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 21, 2026. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

Chugai Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

  • The company reported a strong earnings per share (EPS) of $0.22 for the latest quarter, indicating solid profitability.
  • Chugai Pharmaceutical Co., Ltd. has a high return on equity of 22.00%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
  • The current stock price is around $27.48, which is relatively stable compared to its 12-month high of $34.84, indicating potential for growth.
  • Analysts have recently upgraded the stock to a "strong-buy" rating, reflecting positive sentiment and confidence in the company's future performance.
  • The company focuses on oncology and immunology, areas with significant growth potential due to increasing demand for innovative treatments.

Chugai Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

  • The stock has experienced a decline of about 1.4% recently, which may indicate short-term volatility and investor uncertainty.
  • Chugai Pharmaceutical Co., Ltd. has a price-to-earnings (P/E) ratio of 31.58, which is relatively high and may suggest that the stock is overvalued compared to its earnings.
  • The company's market cap of $90.44 billion may limit its growth potential, as larger companies often face challenges in maintaining high growth rates.
  • With a beta of 0.69, the stock is less volatile than the market, which may appeal to conservative investors but could also mean less opportunity for high returns.
  • Recent trading volume was lower than average, which could indicate reduced investor interest and liquidity concerns.

CHGCY Forecast - Frequently Asked Questions

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" CHGCY shares.

According to analysts, Chugai Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Chugai Pharmaceutical's stock had 1 upgrade by analysts.

Chugai Pharmaceutical has been rated by research analysts at Smbc Nikko Sec. in the past 90 days.

Analysts like Chugai Pharmaceutical more than other "medical" companies. The consensus rating for Chugai Pharmaceutical is Strong Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CHGCY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Chugai Pharmaceutical Recommendations


This page (OTCMKTS:CHGCY) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel